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Abstract
Background: Microalbuminuria (MA) is a risk marker for diabetic nephropathy and cardiovascular (CV) dis-
ease (CVD) in patients with diabetes. This study aimed to describe the prevalence of albuminuria, CV risk fac-
tors, and treatments for renal and CV protection in an Asian population with type 2 diabetes.
Methods: This cross-sectional study conducted in eight Asian countries enrolled normotensive/hypertensive
adults with type 2 diabetes without known proteinuria and/or non-diabetic kidney disease. Exclusion criteria
were type 1 diabetes, menstruation, pregnancy, and acute fever. A single random urinary albumin/creatinine
test was carried out in all patients.
Results: Of 8,561 patients, 14% had diabetic retinopathy, and 17% and 21% had history of CV disease and smok-
ing, respectively. Normoalbuminuria was seen in 44%, MA in 44%, and macroalbuminuria in 12%. Target gly-
cosylated hemoglobin (HbA1c) (7%) was reached in only 37% of 3,834 patients with available values. Dia-
betes was managed by diet alone in 6%, while others received oral hypoglycemic drugs and/or insulin. In total,
75% did not reach target blood pressure (BP) of 130/80 mm Hg. Antihypertensive drugs were prescribed to
52%, with the number of drugs increasing as the level of systolic BP increased. Drugs blocking the renin–an-
giotensin system were most commonly prescribed, followed by calcium channel blockers. Lipid-lowering drugs
and anticoagulant/antiplatelet agents were used in about 30% and 25% of patients, respectively.
Conclusions: Asian patients with type 2 diabetes had a high prevalence of MA and reduced kidney function.
Furthermore, BP and HbA1c control was only achieved in a minority of patients. Aggressive risk management
by administration of reno- and cardioprotective treatments is urgently needed.
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Introduction
MICROALBUMINURIA (MA), which is defined as an abnor-mal increase in the rate of urinary excretion of albu-
min to between 30 and 300 mg/24 h, was first described in
patients with diabetes mellitus in 1969.1 It is the earliest man-
ifestation of diabetic kidney disease in both type 1 and type
2 diabetes and a strong risk marker for the progression of
nephropathy.2 Several prospective epidemiologic studies
have also demonstrated that MA is an important risk factor
for cardiovascular (CV) disease (CVD) in patients with type
2 diabetes. A meta-analysis of these studies showed that the
1Chinese PLA General Hospital, Beijing, People’s Republic of China.
2Taipei Veterans General Hospital, Taipei, Republic of China.
3Ciptomangunkusumo General Hospital, Jakarta, Indonesia.
4King Chulalongkorn Memorial Hospital, Bangkok, Thailand.
5Alexandra Hospital, Singapore.
6Department of Medicine, University of Hong Kong, Queen Mary Hospital, Hong Kong.
7Pantai Medical Centre, Kuala Lumpur, Malaysia.
8sanofi-aventis, Paris, France.
9Korea University Medical Center, Seoul, Republic of Korea.
presence of MA doubled the risk of CV morbidity or mor-
tality.3
Besides its role in diabetic nephropathy, MA is also asso-
ciated with essential hypertension,4 ischemic heart disease,5
atherosclerosis,6 acute stroke,7 and diastolic dysfunction8
and is an independent powerful risk factor for fatal and non-
fatal vascular events and all-cause mortality in subjects with-
out diabetes.9,10 In fact, Ibsen et al.11 showed that a reduc-
tion in urinary albumin excretion was associated with a
reduction in CV events in hypertensive patients treated with
blockade of the renin-angiotensin system (RAS).
In the last 4 decades, the knowledge about MA and its im-
plications has grown significantly. Guidelines such as the
ones produced by the American Diabetes Association (ADA)
recommend annual screening for MA in patients with dia-
betes.12 However, since MA is not associated with clinical
symptoms, it is often underdiagnosed, and the awareness of
its importance as renal and CV risk marker is still poor. Sev-
eral interventional studies aiming at improved glycemic con-
trol and blockade of the RAS have shown that the onset of
diabetic nephropathy can be postponed in patients with type
2 diabetes with normoalbuminuria and/or MA.13–15 Despite
the knowledge about early identification and intervention in
high-risk patients with type 2 diabetes, diabetic nephropa-
thy is still the leading cause of end-stage renal disease in
most countries of the world.16 Thus, it is critically important
to identify incident kidney disease in patients with diabetes
at the earliest stage by screening for MA in order to best pre-
vent evolution to overt nephropathy and subsequent end-
stage renal disease.
In 2003, the International Diabetes Federation and the In-
ternational Society of Nephrology developed the theme “Di-
abetes could cost you your kidneys: act now!” In collabora-
tion with these organizations, a study was created on
Developing Education on Microalbuminuria for Awareness
of Renal and CV risk in Diabetes (DEMAND). This cross-sec-
tional, global, clinic/medical center-based study described
the prevalence and risk factors for MA and implementation
of CV protective treatment in normotensive and hyperten-
sive patients with type 2 diabetes without known protein-
uria and/or kidney disease not due to diabetes.17 We pres-
ent here data from Asia, including the People’s Republic of
China, Hong Kong, Indonesia, the Republic of Korea,
Malaysia, Singapore, the Republic of China, and Thailand.
Materials and Methods
Study design
The DEMAND study was a multinational, cross-sectional,
clinic/medical center-based study designed to evaluate the
prevalence and determinants of MA and macroalbuminuria
in patients with type 2 diabetes by random screening at each
participating center during the interval from June to Sep-
tember 2003. The goal was to enroll 10 patients with type 2
diabetes per center. The study was mainly performed in pri-
mary care settings. The study was endorsed and the centers
selected by local diabetes associations in collaboration with
Bristol-Myers Squibb (New York, NY) and sanofi-aventis
(Paris, France). A total of eight different countries in Asia,
including the People’s Republic of China (50 sites), Hong
Kong (74 sites), Indonesia (30 sites), the Republic of Korea
(20 sites), Malaysia (50 sites), Singapore (97 sites), Republic
of China (14 sites), and Thailand (nine sites) participated. The
study protocol was approved by the Ethics Committee of
each participating clinic, and all patients gave written in-
formed consent.
Patients
Eligible patients were normotensive or hypertensive
women and men between 18 and 80 years with type 2 dia-
betes mellitus (World Health Organization criteria) without
prior known proteinuria and/or kidney disease due to dia-
betes. Exclusion criteria included type 1 diabetes mellitus,
menstruation, pregnancy, and acute fever.
Concomitant medications such as cimetidine (which may
falsely elevate creatinine levels) and drugs containing azo
dyes, nitrofurantoin, and riboflavin (which affect the read-
ability of the reagent strips) were prohibited. Contamination
of the urine specimen with soaps, detergents, antiseptics, or
skin cleansers or the use of urine preservatives other than
boric acid (1.0 g/L) was also restricted.
Investigations
All participating general practitioners, physicians, and
nurses received the study protocol and were instructed in
performing the urinary albumin/creatinine test (single de-
termination) and blood pressure (BP) measurement with an
appropriate cuff after approximately 10 min of rest in the sit-
ting position (single recording).
Furthermore, demographic profile (age, gender, ethnicity,
and region), clinical characteristics (height, body mass index
[BMI], known duration of diabetes, glycosylated hemoglo-
bin [HbA1c], and serum creatinine), medical history (reti-
nopathy, diabetic foot lesion, CVD, smoking, hyperlipi-
demia, and family history of diabetes/hypertension/CVD),
and simultaneous treatments (glucose-lowering treatment,
antihypertensive agents, lipid-lowering drugs, and anti-
platelet/anticoagulant agents) for each patient were re-
corded on a single-page clinical report form.
Presence of CVDs such as coronary artery disease, myo-
cardial infarction, left ventricular hypertrophy, congestive
heart failure, stroke, transient ischemic attack, or peripheral
vascular disease was based on medical records and infor-
mation obtained during the interview. Standardized defini-
tions of the different CVDs were not applied. Presence of hy-
perlipidemia was based on objective measurements as stated
in the medical records. Presence of arterial hypertension was
based on medical history of patients receiving BP-lowering
therapy.
A single random urine albumin/creatinine ratio was mea-
sured using Bayer reagent strip Multistix® 10SG (Siemens
Medical Solutions Diagnostics, Tarrytown, NY and Los An-
geles, CA). According to this semiquantitative strip test, nor-
moalbuminuria is defined as albumin-to-creatinine ratio 30
mg/g, MA as 30–299 mg/g, and macroalbuminuria as 300
mg/g. According to the manufacturer, the Multistix 10SG
test has a sensitivity of 84% and specificity of 91% for the al-
bumin-to-creatinine ratio. Urine samples with concentra-
tions of creatinine of 10 mg/dL were discarded as too di-
lute, as prespecified in the protocol.
We used the Modification of Diet in Renal Disease 2 for-
mula to calculate the estimated glomerular filtration rate
(eGFR) (in mL/min/1.73 m2).18 The stages of chronic kidney
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disease were defined according to the American National
Kidney Foundation: stage 1, eGFR 90; stage 2, eGFR 60–89;
stage 3, eGFR 30–59; stage 4, 15–29; and stage 5, eGFR 15
or dialysis.19 Patients in stage 1 and 2 needed to have struc-
tural or functional abnormalities of the kidney, for example,
MA/macroalbuminuria, to be classified as having chronic
kidney disease. An eGFR of 60 mL/min/1.73 m2 is defined
as renal insufficiency.
Statistical analysis
Univariate comparisons of the impact of independent vari-
ables on the average levels of continuous and categorical de-
pendent variables were made using one-way analysis of vari-
ance and the 2 statistic, respectively. A minimal multivari-
ate model predicting the level of albuminuria (normal albu-
minuria, MA, or macroalbuminuria) was constructed using
“proportional odds” ordinal logistic models as realized by
the function lrm for S.19 Parallel models predicting the al-
bumin/creatinine ratio (log transformed) as a continuous
variable were built using ordinary linear regression models
and gave comparable results. To build these models, inde-
pendent variables were added to the model in the order in
which they increased the total likelihood of the model, taken
as a measure of explanatory power, until no further addi-
tions significantly (P  0.05) improved the likelihood, using
the likelihood ratio test. All data management was per-
formed using SAS for Windows version 9.0 (SAS Institute,
Cary, NC), and all analyses were performed using S-Plus
version 6.2 for Windows (Insightful Corp., Seattle, WA).
Results
A total of 8,561 patients were included in the study. Their
characteristics are shown in Table 1. Overall, the mean age
was 60 years, the gender distribution was 50/50, and the
mean duration of diabetes was 7.3 years. Diabetic retinopa-
thy was present in 14%, while 17% had history of CVD, and
21% had history of smoking. The mean HbA1c was 7.8%
(data missing for 55% of patients), and HbA1c was at target
level (7%) in only 37% of 3,834 patients for whom the val-
ues were available.
Medical treatments received by patients are presented in
Table 2. Only 6% of patients with type 2 diabetes were man-
aged with diet alone, whereas the remaining received oral
hypoglycemic drugs and/or insulin. Among the 8,561 pa-
tients, 250 (3%) had missing data with regard to antihyper-
tensive drug use. Antihypertensive drugs were prescribed to
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TABLE 1. CHARACTERISTICS OF PATIENTS
WITH TYPE 2 DIABETES
Characteristics (n  8,561) n %
Demographic
Countries and regions
People’s Republic of China 4,238 50
Hong Kong 403 5
Indonesia 770 9
Republic of Korea 184 2
Malaysia 181 2
Singapore 499 6
Republic of China 1,648 19
Thailand 638 7
Gender
Male 4,208 49
Female 4,314 50
Missing 39 1
Age (years) (mean  SD) 60.2  11.6
20s 63 1
30s 323 4
40s 1,279 15
50s 2,333 27
60s 2,579 30
70s 1,688 20
80s 178 2
Missing 118 1
Ethnicity
White 2 1
Black 1 1
Asian 7,842 92
Hispanic 0 0
Other 0 0
Missing 716 8
Clinical (n  8,561)
BMI (kg/m2) 24.7  3.9
Missing 116 1
Duration of diabetes (years) 7.3  6.2
Missing 642 8
HbA1c (%) 7.8  1.8
Missing 4,727 55
Medical history (n  8,561)
Family history of diabetes 3,234 38
Family history of CVD 1,490 17
Smoking history 1,794 21
History of hyperlipidemia 3,276 38
History of CVD 1,461 17
History of retinopathy 1,217 14
History of diabetic foot 314 4
TABLE 2. MEDICAL TREATMENT IN PATIENTS
WITH TYPE 2 DIABETES
Treatment n %
Glucose-lowering
Diet-alone 514 6
Oral hypoglycemic agent 6,577 77
Insulin 637 7
Both oral hypoglycemic agent and insulin 774 9
Missing 59 1
Antihypertensive treatment
On no antihypertensive medications 4,110 48
Diuretics 891 10
ACEI 1,905 22
ARB 735 9
Calcium channel blockers 1,902 22
Alpha blockers 190 2
Other antihypertensive agents 367 4
Lipid-lowering agents
Statin 1,521 18
Other lipid-lowering agents 1,016 12
On anticoagulant/antiplatelet agents
Aspirin 1,809 21
Warfarin 28 1
On other anticoagulant/antiplatelet agents 273 3
ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin
receptor blocker.
4,451 (52%) patients. Drugs blocking the RAS, followed by
calcium channel blockers and diuretics, were most com-
monly used. The number of BP-lowering drugs prescribed
increased with the level of systolic BP (SBP). The percentage
of patients not receiving antihypertensive medication
dropped from approximately 36% at a SBP of 140 mm Hg to
approximately 14% at a SBP of 200 mm Hg. Only 30% of pa-
tients received lipid-lowering drugs, and anticoagulant/an-
tiplatelet agents were given to about 25% of patients.
Normoalbuminuria was demonstrated in 44% and MA in
44%, and the remaining 12% had macroalbuminuria (Table
3). Overall, eGFR averaged 78  127 mL/min/1.73 m2 (data
missing in 67% of patients). In the subset of patients with
data permitting estimation of glomerular filtration rate (n 
2,841), 23% had renal insufficiency, that is, eGFR 60
mL/min/1.73 m2. While 61% of patients did not achieve tar-
get SBP (130 mm Hg), 62% did not achieve target diastolic
BP (DBP) 80 mm Hg. In total, 6,250 (75%) had SBP 130
mm Hg and/or DBP 80 mm Hg.
Discussion
In this Asian cross-sectional study of patients with type 2
diabetes without previously known proteinuria or kidney
disease, approximately 56% had MA or macroalbuminuria.
Although serum creatinine data were missing in two-third
of our patients, renal insufficiency was detected in 23% of
those with available data. This large clinic/medical center-
based study confirms and extends previous observations
suggesting a high prevalence of MA in several Asian coun-
tries.20–22 Our results highlight the need for more regular and
earlier testing of MA to detect the presence of kidney dis-
ease due to diabetes. In fact, based on abundant evidence
showing that MA predicts both renal and CV outcomes in
patients with diabetes and in the general population, the lat-
est European guidelines now include MA in routine testing
because it is simple and cheap and has good predictive
value.23
The main strength of our study was that it included a large,
multinational referred cohort of subjects with type 2 diabetes
in Asia with validated identification of predefined primary
and secondary end points. Although there are other single-
country studies assessing kidney function,20–22 there are very
few large multinational studies on MA in Asian subjects with
diabetes and hypertension.24 Moreover, our study enrolled
a higher number of Asian patients and was part of a much
larger global study to establish worldwide prevalence and
risk factors of MA in patients with diabetes. Our study also
had some limitations. First, we carried out only a single mea-
surement of urinary albumin/creatinine ratio and arterial
BP. However, the large sample size and the high frequency
of diagnostic abnormality detected with a single urine col-
lection minimize the uncertainty associated with day-to-day
differences in urinary albumin excretion, and single mea-
surement has been shown to be a useful tool for assessing
MA in large epidemiological studies. A second limitation
was that since we only looked at patients’ historical data on
lipids and HbA1c values, there was no standardized method
for determining these values. Although cigarette smoking is
a strong and modifiable risk factor for macrovascular dis-
ease in patients with diabetes,25 we did not collect data on
current smoking history. An additional limitation that may
potentially confound the results of this regional analysis is
the fact that almost 50% of patients were contributed by the
Republic of China alone. Hence, because of unequal repre-
sentation from different countries, the results may not be uni-
formly applicable to the eight participating Asian countries.
Since our study was not population-based, there is a possi-
bility of selection bias in relation to the participating centers.
However, the prevalence of MA or macroalbuminuria in our
study (56%) is comparable with 58.6% observed in a cross-
sectional study of consecutively screened 5,549 patients with
type 2 diabetes from 10 Asian countries.24
Our study revealed an increased prevalence of several vas-
cular risk factors. Patients with type 2 diabetes have a two
to six times higher risk of fatal and non-fatal CV events than
subjects without diabetes.3,26,27 Patients with MA and
macroalbuminuria suffer the highest risk, possibly because
of several modifiable risk factors such as hypertension, dys-
lipoproteinemia, and increased platelet aggregability. Ran-
domized double-blind trials in patients with type 2 diabetes
demonstrated benefits of intensified intervention involving
a single vascular risk factor on macro- and microvascular
disease.27–30 The Steno-2 study revealed that an intensified,
targeted, multifactorial intervention aimed at several modi-
fiable risk factors in patients with type 2 diabetes and MA
reduced the risk of CV and microvascular events by about
half.31,32 The latest scientific statement from the American
Heart Association (AHA) and the ADA for the primary pre-
vention of CVD in people with diabetes also recommends
comprehensive risk assessment and broad-based treatment
of risk factors.32
The average HbA1c in our study was lower than that re-
ported in the intensive treatment arm of the Steno-2 study.31
However, values were missing in 63% of our patients. Only
37% patients (of 3,834 with HbA1c values) achieved target
HbA1c (7%), attesting the fact that in some cases the man-
agement of glycemia was less aggressive than desired.
Among those with the highest HbA1c levels, many patients
were not started on insulin therapy.
A target BP of 130/80 mm Hg is recommended in pa-
tients with type 2 diabetes.34 In our study, the majority of
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TABLE 3. ALBUMINURIA, KIDNEY FUNCTION, AND
ARTERIAL BP IN PATIENTS WITH TYPE 2 DIABETES
Variable Value %
Albuminuria
None 3,794 44
MA 3,753 44
Macroalbuminuria 1,014 12
Log 2 (albumin/creatinine ratio) 37 (2.9–467)a
(mg of albumin/g of creatinine)
Serum creatinine (mg/dL) 1.01  0.40
Missing 5,700 67
MDRD GFR (mL/min) 78  127
Missing 5,720 67
SBP (mm Hg) 133  18
Missing 250 3
DBP (mm Hg) 79  10
Missing 258 3
MDRD GFR, modification of diet in renal disease glomerular fil-
tration rate.
aThe 95% confidence interval is given in parentheses.
patients had uncontrolled BP, and yet almost half of these
patients did not receive BP-lowering therapy, despite the
well-documented benefit on large and small vessel disease.35
A study by Ramirez et al.36 suggested that the association
between SBP or DBP and proteinuria did not seem to have
a minimal threshold level because a trend for an increase in
odds for proteinuria was observed even with BP measure-
ments within the recommended range. The fact that even
mild BP elevations were associated with proteinuria in a
multi-ethnic population from Singapore might suggest that
normal BP values for Asians are not equivalent to those es-
tablished for Caucasians and indicates the need to establish
BP nomograms specific to the Asian population.36 The most
frequently used antihypertensive drugs were agents block-
ing the RAS, followed by calcium channel blockers. The
AHA-ADA guidelines recommend an antihypertensive reg-
imen containing an angiotensin-converting enzyme inhibi-
tor or an angiotensin-receptor blocker.32 Nonetheless, even
these drugs were utilized in only 30% of our patients. A com-
bination of drugs is often needed for adequate BP control in
patients with diabetes—although angiotensin-converting en-
zyme inhibitors and angiotensin-receptor blockers are the
preferred first-line agents, a low-dose thiazide diuretic gen-
erally should be one of the first two drugs used.32 However,
diuretics were underused (only 10%) in our study. While the
emphasis is on tight BP control to reduce morbidity, the ac-
tual choice of drug should be individually decided by the
physician.37 Since most patients in our study were only on
one or two classes of antihypertensive agents even at the
highest SBP, the treatment of hypertension needs to be more
aggressive.
Several statin trials have demonstrated a beneficial effect
on CV events, including ischemic stroke, in patients with
type 2 diabetes.28,29,38 Furthermore, since these drugs are
safe, there is a strong argument that type 2 diabetes patients
warrant statin treatment.39 Although 38% patients had his-
tory of hyperlipidemia, lipid-lowering therapy was only
recorded in 30% of patients, despite these patients having a
high frequency of several conventional CV risk factors in-
cluding MA and macroalbuminuria. Even among patients
with a history of hyperlipidemia, only 38% received statins.
A large meta-analysis of the use of antiplatelet agents
clearly indicates a CV benefit in diabetes.40 Low-dose ther-
apy with aspirin (or another antiplatelet agent) is recom-
mended as a primary prevention strategy in those with dia-
betes at increased CV risk, including those who are 40 years
of age or who have additional risk factors (family history of
CVD, hypertension, smoking, dyslipidemia, or albumin-
uria).33 While a large proportion of patients in our study had
one or more of these risk factors, only one-fourth of the pa-
tients received antiplatelet agents.
To summarize, there is a high prevalence of MA and
macroalbuminuria and reduced kidney function, conditions
associated with adverse renal and CV events, in Asian pa-
tients with type 2 diabetes without prior known nephropa-
thy. MA is known to be more prevalent in South Asian in-
dividuals than in white Europeans, which is consistent with
the observation that they are at greater risk for CV compli-
cations compared to white Europeans.41,42 A study by Dixon
et al.42 showed that almost one-third of South Asian patients
with diabetes having untreated normal BP had MA. This in-
creased prevalence of MA, even in normotensive subjects,
suggests that the threshold for intervention and the target
for therapy of CV risk factors in South Asian patients with
type 2 diabetes should be lower than for white Europeans.42
In conclusion, early detection of MA, monitoring of vascu-
lar complications, and more aggressive multifactorial treat-
ment aiming at renal and vascular protection are urgently
needed.
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